Resistance to Antiestrogen Therapy in Hormone Receptor-Positive Breast Cancer

激素受体阳性乳腺癌对抗雌激素治疗的耐药性

• 批准号: 8270581
• 负责人: Carlos L Arteaga
• 金额: $ 30.25万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8270581
• 关键词: 1-Phosphatidylinositol 3-Kinase; Adjuvant; Antiestrogen Therapy; Aromatase Inhibitors; Biological Assay; Biological Markers; Breast Cancer Cell; Cancer cell line; Cell Proliferation; Clinical; Clinical Data; Clinical Trials; Data; Dependence; Disease; Drug resistance; ERBB2 gene; Endocrine; Estrogen Antagonists; Estrogen Receptor Modulators; Estrogen receptor positive; Estrogens; Exhibits; Formalin; Gene Expression Profile; Genes; HER2 inhibition; Hormonal; Hormone Receptor; Hormones; Immunohistochemistry; In complete remission; Inhibition of Cell Proliferation; Letrozole; Malignant Neoplasms; Mammary Neoplasms; Measures; Molecular; Molecular Profiling; Natural History; Neoadjuvant Therapy; PTEN gene; Pathologic; Pathway interactions; Patients; Pharmacodynamics; Proto-Oncogenes; Recurrence; Resistance; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Specimen; Tamoxifen; Therapeutic; Treatment Failure; Tumor Tissue; Tyrosine Kinase Inhibitor; base; cancer cell; chemotherapy; deprivation; directed attention; gene discovery; hormone therapy; inhibitor/antagonist; lapatinib; malignant breast neoplasm; novel; overexpression; prospective; response; standard care; success; therapy design; tumor

The treatment for hormone receptor-positive breast cancer includes therapies designed to block estrogen action. Although these therapies have changed the natural history of hormone-dependent breast cancer, many tumors exhibit ofe novo or acquired endocrine resistance. Studies with human breast cancer cell lines as well as molecular profiling of primary mammary tumors have identified molecular alterations associated with hormonal independence and drug resistance. One of these mechanisms is overexpression of the HER2 (ErbB2) protooncogene and its signaling network. Overexpression of HER2 is the only mechanism of antiestrogen resistance for which prospective clinical data exist. However, only <10% of hormone-dependent breast cancer express high levels of HER2, suggesting that for the majority of hormone-receptor positive breast cancers, mechanisms of escape from endocrine therapy remain to be discovered. In addition to the substantial improvements of antiestrogen therapy, assays have been developed to predict the odds of benefit from it. These assays do not identify the molecular alteration causally associated with treatment failure and tumor recurrence. More recently, cancer cell proliferation as measured by Ki67 immunohistochemistry in the tumor specimen after neoadjuvant hormonal therapy has been shown to correlate with disease-free and overall survival. These data suggest that pharmacodynamic biomarkers of the cellular and molecular effects of endocrine therapy in the breast tumor, likely because they incorporate the effects of therapy, can be used to identify cancers that are highly hormone-dependent and thus sensitive to endocrine treatment vs. those that are cfe novo resistant and/or destined to recur faster. We hypothesize that those tumors exhibiting a marked inhibition of cell proliferation are likely to do well on adjuvant hormonal therapy alone whereas those that do not, are destined to an early recurrence. To 1) determine if inhibition of HER2 function reverses resistance to endocrine therapy, and 2) discover novel mechanisms associated with resistance to endocrine therapy in hormone receptor-positive tumors without HER2 overexpression, we propose the following aims: Aim 1: To determine if combined neoadjuvant therapy with the aromatase inhibitor letrozole and the HER2 tyrosine kinase inhibitor lapatinib induces pathologic complete responses in hormone receptor-positive breast cancers that overexpress HER2 and establish biomarkers predictive of response to this therapy. Aim 2: To determine if the post-letrozole Ki67 in hormone receptor-positive/HER2-negative tumors mirrors the recurrence score as measured by RT-PCR of 21 selected genes in formalin-fixed tumor tissue sections and to use these biomarkers to discover gene expression signatures associated with hormonal dependence. Aim 3: To determine the mechanisms by which loss of PTEN in hormone receptor-positive breast cancer cells dysregulates phosphatidylinositol-3 kinase (PI3K) signaling and generates resistance to antiestrogens.

激素受体阳性乳腺癌的治疗包括旨在阻断雌激素作用的治疗。虽然这些治疗改变了激素依赖型乳腺癌的自然病史，但许多肿瘤表现出新生或获得性内分泌抵抗。对人类乳腺癌细胞系的研究以及对原发性乳腺肿瘤的分子图谱分析已经确定了与此相关的分子变化 具有荷尔蒙独立性和抗药性。其中一个机制是HER2(ErbB2)原癌基因及其信号网络的过度表达。HER2的过度表达是存在预期临床数据的抗雌激素抵抗的唯一机制。然而，只有10%的激素依赖者 乳腺癌表达高水平的HER2，这表明对于大多数激素受体阳性的乳腺癌来说，逃避内分泌治疗的机制仍有待发现。除了抗雌激素治疗的实质性改进外，还开发了预测受益几率的检测方法。这些检测不能确定与治疗失败和肿瘤复发相关的分子改变。最近，新辅助激素治疗后肿瘤标本中Ki67免疫组织化学检测的癌细胞增殖已被证明与无病和总存活率相关。这些数据表明，乳腺肿瘤内分泌治疗的细胞和分子效应的药效学生物标志物，可能是因为它们包含了治疗效果，可以用来识别高度依赖激素并因此对内分泌治疗敏感的癌症，而不是那些CFE新耐药和/或注定复发更快的癌症。我们假设，那些表现出明显的细胞增殖抑制的肿瘤，很可能单独使用辅助激素治疗效果良好，而那些不这样做的肿瘤，注定会早期复发。为了1)确定HER2功能抑制是否逆转了内分泌治疗的抵抗，以及2)在激素受体阳性但没有HER2过表达的肿瘤中发现与内分泌治疗抵抗相关的新机制 提出以下目标： 目的1：确定芳香化酶抑制剂来曲唑和HER2联合新辅助治疗 酪氨酸激酶抑制剂拉帕替尼诱导激素受体阳性患者的病理完全反应 过度表达HER2并建立生物标记物预测对该疗法的反应的乳腺癌。 目的：确定激素受体阳性/HER2阴性肿瘤中来曲唑后Ki67的表达是否能反映福尔马林固定的肿瘤组织切片中21个特定基因的复发评分，并利用这些生物标记物发现与激素依赖相关的基因表达特征。 目的：探讨激素受体阳性的乳腺癌细胞中PTEN基因缺失导致磷脂酰肌醇-3激酶(PI3K)信号转导紊乱并产生抗雌激素耐药的机制。